pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
CRISPR/Cas9 · news · pharmadog
← back to CRISPR/Cas9
News · CRISPR/Cas9
99
stories
9h
Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths
biospace
1d
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
1d
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
2d
STAT+: Experts scrutinize Huidagene’s disclosures after patient death
stat
2d
STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
stat
2d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
stat
2d
STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
stat
7d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
8d
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction
endpoints
10d
Epicrispr secures $90M after early data on epigenetic FSHD treatment
endpoints
10d
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
biopharma dive
11d
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
12d
STAT+: A shortage of two Sanofi medicines for Pompe disease rattles patients
stat
14d
STAT+: NIH plans to block international researchers on visas from accessing key funding avenue
stat
14d
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharma dive
14d
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
15d
Intellia identifies genetic risk factor for liver complications in CRISPR trial
endpoints
15d
FDA approves Moderna’s mRNA flu vaccine, the first to use the technology
stat
16d
STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
stat
16d
STAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI
stat
16d
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
stat
16d
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
biospace
16d
STAT+: Moderna launches early trial of Ebola mRNA vaccine
stat
16d
STAT+: Senate inquiry suggests Trump administration softened kratom and tobacco policies in quid pro quo
stat
16d
STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
stat
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
17d
Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges
stat
17d
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
stat
← prev
page 1 of 4
next →
